Oscotec Inc. (KOSDAQ:039200)
59,600
+4,300 (7.78%)
Dec 10, 2025, 3:30 PM KST
Oscotec Revenue
Oscotec had revenue of 8.95B KRW in the quarter ending September 30, 2025, a decrease of -69.21%. This brings the company's revenue in the last twelve months to 23.23B, down -27.34% year-over-year. In the year 2024, Oscotec had annual revenue of 34.01B with 586.89% growth.
Revenue (ttm)
23.23B
Revenue Growth
-27.34%
P/S Ratio
91.06
Revenue / Employee
438.39M
Employees
53
Market Cap
2.12T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 34.01B | 29.06B | 586.89% |
| Dec 31, 2023 | 4.95B | -111.45M | -2.20% |
| Dec 31, 2022 | 5.06B | 1.16B | 29.71% |
| Dec 31, 2021 | 3.90B | -39.57B | -91.02% |
| Dec 31, 2020 | 43.47B | 39.10B | 895.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |